Azacitidine
Contents
Description
Azacitidine is a hypomethylating agent used in the treatment of myelodysplastic syndromes and acute myeloid leukemia. It works by inhibiting DNA methyltransferase, leading to hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells. The drug has shown efficacy in treatment-related myelodysplastic syndromes including those related to prior chemotherapy exposure.
Indications & Therapeutic Use
Myelodysplastic syndromes, acute myeloid leukemia with 20-30% blasts, chronic myelomonocytic leukemia
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Azacitidine — GNH India
240 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | Azacitidine |
| Brands | 1 brand available |
| Active Ingredient | Azacitidine |
| Drug Class | Myelodysplastic syndromes |
| Manufacturer | Celgene |
| Dosage Forms | Subcutaneous injection, 100mg vial; IV infusion |
| Medical Code | L01BC07 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 5 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00071799 |
| Countries | 8 countries |